TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06507826

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Compassionate Writing for Caregivers of Older Adults
Description: Self-compassionate writing focusing on one or more self-compassion components (mindfulness, self-kindness, common humanity).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Self-Compassionate Writing for Caregivers of Older Adults
Description: Self-compassionate writing focusing on one or more self-compassion components (mindfulness, self-kindness, common humanity).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Self-Compassionate Writing for Caregivers of Older Adults
Description: Self-compassionate writing focusing on one or more self-compassion components (mindfulness, self-kindness, common humanity).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Compassionate Writing for Caregivers of Older Adults
Description: Self-compassionate writing focusing on one or more self-compassion components (mindfulness, self-kindness, common humanity).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Compassionate Writing for Caregivers of Older Adults
Description: Self-compassionate writing focusing on one or more self-compassion components (mindfulness, self-kindness, common humanity).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Compassionate Writing for Caregivers of Older Adults
Description: Self-compassionate writing focusing on one or more self-compassion components (mindfulness, self-kindness, common humanity).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Compassionate Writing for Caregivers of Older Adults
Description: Self-compassionate writing focusing on one or more self-compassion components (mindfulness, self-kindness, common humanity).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Self-Compassionate Writing for Caregivers of Older Adults
Description: Self-compassionate writing focusing on one or more self-compassion components (mindfulness, self-kindness, common humanity).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Compassionate Writing for Caregivers of Older Adults
Description: Self-compassionate writing focusing on one or more self-compassion components (mindfulness, self-kindness, common humanity).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Compassionate Writing for Caregivers of Older Adults
Description: Self-compassionate writing focusing on one or more self-compassion components (mindfulness, self-kindness, common humanity).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Compassionate Writing for Caregivers of Older Adults
Description: Self-compassionate writing focusing on one or more self-compassion components (mindfulness, self-kindness, common humanity).
Study: NCT06393647

Intervention type: OTHER
Intervention: Frailty scale forms (Frailty Scale Version 9, Quality of Life Scale Short Form-36)
Description: In our study, we aim to investigate the relationship between frailty status assessed using frailty scale forms (Frailty Scale Version 9, Quality of Life Scale Short Form-36) and preoperative levels of Albumin/Creatinine, B12, Folate, Ferritin, Sedimentation Rate, and CRP in patients undergoing gastrointestinal malignancy surgery.

Intervention type: OTHER
Intervention: Frailty scale forms (Frailty Scale Version 9, Quality of Life Scale Short Form-36)
Description: In our study, we aim to investigate the relationship between frailty status assessed using frailty scale forms (Frailty Scale Version 9, Quality of Life Scale Short Form-36) and preoperative levels of Albumin/Creatinine, B12, Folate, Ferritin, Sedimentation Rate, and CRP in patients undergoing gastrointestinal malignancy surgery.
Study: NCT05386693

Intervention type: PROCEDURE
Intervention: Ilioinguinal nerve block
Description: Local anesthetic injection of the ilioinguinal nerve. This is performed in the outpatient clinic.
Study: NCT04745897

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eTB Catalogue of Recommendations (eTB)
Description: eTB Catalogue of Recommendations (eTB)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: World Health Organization Tuberculosis Website (WHO TB)
Description: World Health Organization Tuberculosis Website (WHO TB)
Study: NCT05769959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7515629
Description: RO7515629 will be administered intravenously at a dose and schedule as specified for the respective study part and cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7515629
Description: RO7515629 will be administered intravenously at a dose and schedule as specified for the respective study part and cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7515629
Description: RO7515629 will be administered intravenously at a dose and schedule as specified for the respective study part and cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab
Description: Tocilizumab will be used as rescue medication only. Tocilizumab will be administered as required for the management of cytokine release syndrome (CRS).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab
Description: Tocilizumab will be used as rescue medication only. Tocilizumab will be administered as required for the management of cytokine release syndrome (CRS).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab
Description: Tocilizumab will be used as rescue medication only. Tocilizumab will be administered as required for the management of cytokine release syndrome (CRS).
Study: NCT04809142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450 Injection
Description: TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib hydrochloride
Description: Anlotinib capsules 12 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin injection
Description: Oxaliplatin injection 130 mg/m2 administered IV on Day 1 of each week in 3-week cycles;

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine tablets
Description: Capecitabine tablets total dose 2000 mg/m2, oral twice a day from Day 1-14 of each 3- week cycles;

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine hydrochloride injection
Description: Gemcitabine hydrochloride injection administered 1000 mg/m2 IV on Day 1 and Day 8 of each week in 3-week cycles.
Study: NCT05574920

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Al18F-NOTA-FAPI-04 PET/CT scan
Description: Patients enrolled underwent PET/CT after injection of Al18F-NOTA-FAPI-04 to image lesions of breast cancer.
Study: NCT05355454

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STYLAGE® XXL
Description: Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek at the first session, on each side of the face.~Up to 1.0 mL in the zygomaticomalar region and optionally up to 1.0 mL in the anteromedial cheek for the optional touch-up session, on each side of the face.~Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek before study exit, on each side of the face.

Intervention type: DEVICE
Group type: OTHER
Intervention: STYLAGE® XXL
Description: Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek at the first session, on each side of the face.~Up to 1.0 mL in the zygomaticomalar region and optionally up to 1.0 mL in the anteromedial cheek for the optional touch-up session, on each side of the face.~Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek before study exit, on each side of the face.
Study: NCT05639556

Intervention type: OTHER
Intervention: Psychosocial questionnaire: The Treatment Self-Regulation Questionnaire (TSRQ)
Description: This is a 15-item scale that assesses the degree to which participants' motivation is autonomous or self-regulated.

Intervention type: OTHER
Intervention: Psychosocial questionnaire: The Treatment Self-Regulation Questionnaire (TSRQ)
Description: This is a 15-item scale that assesses the degree to which participants' motivation is autonomous or self-regulated.

Intervention type: OTHER
Intervention: Psychosocial questionnaire: CF Fatalism Scale
Description: The CF Fatalism Scale measures the belief in a lack of personal power or control over one's future and has 13 items.

Intervention type: OTHER
Intervention: Psychosocial questionnaire: CF Fatalism Scale
Description: The CF Fatalism Scale measures the belief in a lack of personal power or control over one's future and has 13 items.
Study: NCT05118399

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Injection [Marcaine]
Description: Bupivacaine injection \[Marcaine\] is the standard treatment used in our hospital.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Liposome 13.3 MG/ML [Exparel]
Description: Bupivacaine liposome is a multivesicular formulation of bupivacaine that allows rapid absorption and prolonged release of bupivacaine.
Study: NCT04924998

Intervention type: DRUG
Intervention: current treatment of AL-CM
Description: current treatment of AL-CM
Study: NCT04686955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xiao-Xian-Gui-Fu-Tang
Description: The Xiao-Xian-Gui-Fu-Tang includes Xiao-Feng-San 2.0g, Dang-Gui-Yin-Zi 1.2g, Bai-Xian-Pi(Cortex Dictamni Radicis) 0.4g, and Di-Fu-Zi(Fructus Kochiae) 0.5g. The Xiao-Xian-Gui-Fu-Tang will be manufactured, packaged, and labeled by the KO DA Pharmaceutical Company (Taiwan), using good manufacturing practice standards.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Xiao-Xian-Gui-Fu-Tang
Description: The Xiao-Xian-Gui-Fu-Tang includes Xiao-Feng-San 2.0g, Dang-Gui-Yin-Zi 1.2g, Bai-Xian-Pi(Cortex Dictamni Radicis) 0.4g, and Di-Fu-Zi(Fructus Kochiae) 0.5g. The Xiao-Xian-Gui-Fu-Tang will be manufactured, packaged, and labeled by the KO DA Pharmaceutical Company (Taiwan), using good manufacturing practice standards.
Study: NCT05466357

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Excision of pituitary tumor outside pseudocapsule
Description: Dedicated high-resolution magnetic resonance imaging (MRI) protocols have been proposed to detect pituitary adenoma and accurately guide surgical removal. To accomplish complete PA removal and minimize the impact on pituitary functions, intraoperative navigation was used to identify the tumor pseudocapsule. Depending on different tumor sizes and pseudocapsule development, investigators adopted different resection strategies. The suspicious tissue was sent to the pathology department for histopathology intraoperatively. Long-term postoperative follow-up imaging and endocrine data were used to evaluate tumor prognosis before and after operation. Standardized management and established biobank is critical for pituitary adenomas.
Study: NCT06160427

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTM Boost
Description: Connective Tissue Matrix (CTM) Boost is a decellularized Human Cellular and Tissue Based Allograft derived from placental connective tissue. It is considered a minimally-manipulated biologic by the FDA and is marketed as an allograft for repairing connective tissue. It is administered via injection.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRP
Description: PRP is derived by a sample of blood drawn from a patient and concentrated to include mainly platelets and potent inflammatory mediators which promote healing.~At baseline, a blood draw of 60 milliliter (mL) will be obtained and concentrated in an Angel System to yield 5 cc of PRP and a supra-physiological concentration of white blood cells. All injections will be done under ultrasound guidance. A two-part injection process will be used. An advancing 20 gauge 1.5-inch needle first placed 3 mL of 1% xylocaine proximal to the tendinopathic area or tear. The needle will then be re-inserted at the proximal aspect of the lesion and slowly removed while infiltrating of 5 mL of PRP without activation with Calcium Chloride/thrombin at the lesion and surrounding tendon.
Study: NCT05639556

Intervention type: OTHER
Intervention: Psychosocial questionnaire: Body Esteem Scale for Adolescents and Adults (BESAA)
Description: The Body Esteem Scale for Adolescents and Adults (BESAA) is 23-item measurement of self-evaluations of one's body or appearance.

Intervention type: OTHER
Intervention: Psychosocial questionnaire: Body Esteem Scale for Adolescents and Adults (BESAA)
Description: The Body Esteem Scale for Adolescents and Adults (BESAA) is 23-item measurement of self-evaluations of one's body or appearance.
Study: NCT06256393

Intervention type: OTHER
Intervention: Collection of biological samples
Description: Collection of blood samples and intestinal biopsies during a surgery or colonoscopy for disease relapse
Study: NCT05735561

Intervention type: DIAGNOSTIC_TEST
Intervention: X-Ray
Description: Consenting participants will be asked to come into the clinic for a single visit, during this visit they will be asked to complete an x-ray to check for evidence of avascular necrosis.

Intervention type: DIAGNOSTIC_TEST
Intervention: X-Ray
Description: Consenting participants will be asked to come into the clinic for a single visit, during this visit they will be asked to complete an x-ray to check for evidence of avascular necrosis.

Intervention type: DIAGNOSTIC_TEST
Intervention: X-Ray
Description: Consenting participants will be asked to come into the clinic for a single visit, during this visit they will be asked to complete an x-ray to check for evidence of avascular necrosis.
Study: NCT06423911

Intervention type: DRUG
Group type: OTHER
Intervention: olverembatinib
Description: olverembatinib QOD

Intervention type: DRUG
Group type: OTHER
Intervention: olverembatinib
Description: olverembatinib QOD

Intervention type: DRUG
Group type: OTHER
Intervention: Bosutinib
Description: Bosutnib QD
Study: NCT05825898

Intervention type: PROCEDURE
Intervention: Surgery or Transcatheter tricuspid valve intervention
Description: Isolated tricuspid valve surgery or Transcatheter tricuspid valve intervention

Intervention type: PROCEDURE
Intervention: Surgery or Transcatheter tricuspid valve intervention
Description: Isolated tricuspid valve surgery or Transcatheter tricuspid valve intervention
Study: NCT05415696

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Prostatic artery embolization
Description: Patients will undergo PAE with 100-300 µm or 300-500 µm Embospheres following standard PAE technique performed by Interventional Radiology at Stanford University
Study: NCT05507983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Tranexamic acid 1500 mg
Study: NCT05639556

Intervention type: OTHER
Intervention: 12-month Questionnaire
Description: A short questionnaire designed to explore participants' perspectives of the acceptability and feasibility of nutritional assessments used in STRONG-CF will be given to all study participants at the end of the study.

Intervention type: OTHER
Intervention: 12-month Questionnaire
Description: A short questionnaire designed to explore participants' perspectives of the acceptability and feasibility of nutritional assessments used in STRONG-CF will be given to all study participants at the end of the study.
Study: NCT05507983

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, sodium chloride 0.9%
Study: NCT05377528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGEN1571
Description: A fully human monoclonal immunoglobulin-like transcript antagonist antibody administered intravenously.
Study: NCT05639556

Intervention type: OTHER
Intervention: Oral glucose tolerance testing (OGTT)
Description: For subjects without previously diagnosed CFRD, an OGTT will be performed at baseline and 12-months with samples analyzed at the central lab.

Intervention type: OTHER
Intervention: Oral glucose tolerance testing (OGTT)
Description: For subjects without previously diagnosed CFRD, an OGTT will be performed at baseline and 12-months with samples analyzed at the central lab.

Intervention type: DEVICE
Intervention: Continuous glucose monitoring (CGM)
Description: Subjects will wear a Dexcom G6Pro sensor in blinded mode for three 10-day periods to collect comprehensive glucose data.

Intervention type: DEVICE
Intervention: Continuous glucose monitoring (CGM)
Description: Subjects will wear a Dexcom G6Pro sensor in blinded mode for three 10-day periods to collect comprehensive glucose data.

Intervention type: DIAGNOSTIC_TEST
Intervention: Chest CT scans (When available within the past 6 months in medical records)
Description: Standard of Care chest CT images will be drawn from the medical record, as available, from enrolled participants. FEV1 measurements prior to chest CT scans will be recorded to account for possible illness occurring at the time of scanning. Quantitative assessment of the pectoralis muscle area will be performed on the first single axial image above the aortic arch. Any additional standard of care chest CT's that are performed while the participant is enrolled in the study will also be collected and have a quantitative assessment of the pectoralis muscle performed.

Intervention type: DIAGNOSTIC_TEST
Intervention: Chest CT scans (When available within the past 6 months in medical records)
Description: Standard of Care chest CT images will be drawn from the medical record, as available, from enrolled participants. FEV1 measurements prior to chest CT scans will be recorded to account for possible illness occurring at the time of scanning. Quantitative assessment of the pectoralis muscle area will be performed on the first single axial image above the aortic arch. Any additional standard of care chest CT's that are performed while the participant is enrolled in the study will also be collected and have a quantitative assessment of the pectoralis muscle performed.
Study: NCT05377528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGEN1571
Description: A fully human monoclonal immunoglobulin-like transcript antagonist antibody administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGEN1571
Description: A fully human monoclonal immunoglobulin-like transcript antagonist antibody administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGEN1571
Description: A fully human monoclonal immunoglobulin-like transcript antagonist antibody administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGEN1571
Description: A fully human monoclonal immunoglobulin-like transcript antagonist antibody administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: A fully human monoclonal programmed cell death protein 1 antagonist antibody administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: A fully human monoclonal programmed cell death protein 1 antagonist antibody administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: A fully human monoclonal programmed cell death protein 1 antagonist antibody administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botensilimab
Description: A fully human fragment crystallizable-enhanced monoclonal cytotoxic T lymphocyte antigen 4 antibody administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botensilimab
Description: A fully human fragment crystallizable-enhanced monoclonal cytotoxic T lymphocyte antigen 4 antibody administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botensilimab
Description: A fully human fragment crystallizable-enhanced monoclonal cytotoxic T lymphocyte antigen 4 antibody administered intravenously.
Study: NCT06111365

Intervention type: DEVICE
Intervention: CHLOE
Description: the system will provide to the user a CHLOE™ score, which is a blastocyst development prediction value, a discrete grading for blastocyst associated with the likelihood of the embryo reaching the blastocyst stage at Day 5
Study: NCT06165796

Intervention type: DEVICE
Intervention: routine cataract surgery and intraocular lens implantation
Description: routine cataract surgery and intraocular lens implantation

Intervention type: DEVICE
Intervention: routine cataract surgery and intraocular lens implantation
Description: routine cataract surgery and intraocular lens implantation
Study: NCT06321133

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula immediate ending
Description: High flow is immediately ended

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High flow nasal cannula weaning
Description: High flow is gradually weaned by reducing the flow rate
Study: NCT06022185

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Web Based Training on E-health Literacy, Digital Literacy and Healthy Lifestyle Behaviors.
Description: In the trainings planned for elderly individuals, digital literacy and e-health literacy levels will be improved, knowledge and awareness levels of elderly individuals will be increased and they will be provided with information in this direction. healthy lifestyle behaviors.~Personal information form, E-Health Literacy Scale, Acquisition and Confirmation of Health Information in Digital Environment Scale, Healthy Lifestyle Behaviors Scale-II will be used in the research.
Study: NCT05339139

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Dialysis
Description: In this study critically ill adult patients requiring Continuous Renal Replacement Therapy (CRRT) will receive Regional Citrate Anticoagulation (CRA) which will be delivered by multiFiltratePRO system.
Study: NCT04578249

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blue light-blocking goggles
Description: Participants will be randomly assigned to one of the two intervention groups.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Clear goggles
Description: Participants will be randomly assigned to one of the two intervention groups.
Study: NCT04988217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-Alpha2B
Description: Nebulized interferon alpha 2B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-Alpha2B
Description: Nebulized interferon alpha 2B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-Alpha2B
Description: Nebulized interferon alpha 2B

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nebulized placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nebulized placebo
Study: NCT06342843

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Hip Arthroplasty
Description: a surgical procedure in which an orthopaedic surgeon removes the damaged bone and cartilage and replaces this with prosthetic components.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Hip Arthroplasty
Description: a surgical procedure in which an orthopaedic surgeon removes the damaged bone and cartilage and replaces this with prosthetic components.